Bioviva talks at the 2b ahead thinktank future congress in germany
Jun 17 , 2016

Bioviva talks at the 2b ahead thinktank future congress in germany

The 2b AHEAD ThinkTank Future Congress ranks as one of the most attractive events in the European innovation scene. For the last 15 years, 300 leading figures in business and society have gathered annually discuss the future of business, with guests including executive directors and CEOs, innovation managers, marketing leaders, extreme lead users, and innovative entrepreneurs. 2016’s annual congress was exclusively focused on future forecasts, speed and agility being a major driver of growth today. The pace of adoption of new technology will affect the transformation of business models in the following decade. The ThinkTank presents technology road maps of the most important, transformative industries, and reveals which business models are on the verge of a big breakthrough, which disruptive technologies are about the reshape the world of industry, as well as which new markets are set to emerge in the next 10 years.

This year, the 15th annual 2b AHEAD ThinkTank Future Congress 2016 was held on June 14-15, 2016 at Wolfsburg Castle, in Hannover. 2016’s attendees included: Audi, Boing, BMW, Bosch, Coop, Deutsche Bank, Ernst & Young, IBM, KPMG, Lufthansa, Marc O’Polo, Mediamarkt, Porsche, Santander Consumer Bank, SAS, Saturn, Siemens, T-Systems, Unify, Volkswagen, Zurich Insurance, and many others.

Liz Parrish, CEO of BioViva USA Inc. presented at the congress, on the changing perceptions of longevity worldwide, the economic necessity of life extension, and BioViva’s revolutionary gene therapies. Gene therapies represent a new paradigm of disease treatment, and BioViva intends to target and ameliorate the aging process itself; simultaneously alleviating risk and treating conditions including heart disease, Alzheimer’s, sarcopenia, and Parkinsons. Treating age-related disease in isolation has yielded little success to date, and BioViva’s CEO Parrish is a vocal advocate for a longevity focused, paradigm shift in medicine.

The 2b AHEAD ThinkTank is focused on finding advanced innovative engineering solutions to global problems. During the past three years they have invited solution oriented thinkers from various industries, including airlines, banking, and infrastructure. Beginning this year they are also focusing on engineering solutions for the complex problems in medicine and healthcare.

The 2b AHEAD ThinkTank Future Congress is a gathering of luminaries from numerous pioneering fields, and BioViva is ranked today as one of the most innovative and unconventional biotech companies in the field of gene therapy. Global aging trends are creating enormous challenges and spiralling healthcare costs, alongside a backdrop of flatlining economic growth. Adopting a preventative, pro-longevity stance in medicine offers a desirable alternative, both improving productivity and tackling the ever increasing rate of dependency. BioViva seeks to deliver increased longevity and quality years of health; addressing these financial, social and moral challenges through the use of cutting edge gene therapies.

Adam Alonzi

Adam Alonzi is a writer, biotechnologist, documentary maker, futurist, inventor, programmer, and author two novels. He is an analyst for the Millennium Project, and Head of Social Media and Content Creation for BioViva Sciences. Listen to his podcasts here. Read his blog here.